Shuttle Pharmaceuticals Holdings financials
$3.92−4.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$11.9M | -$7.7M | -$5.9M | -$2.3M |
| Net income | -$11.7M | -$9.1M | -$6.6M | -$6.7M |
| Net margin | — | — | — | — |
| Diluted EPS | $-71.60 | $-826.00 | $-882.50 | $-1260.00 |
| EBITDA | -$9.4M | -$5.0M | -$5.9M | -$2.3M |
| Operating cash flow | -$9.5M | -$7.3M | -$5.6M | -$2.7M |
| Free cash flow | -$9.5M | -$7.3M | -$5.6M | -$2.7M |
| Diluted shares | 0.2M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $334.0K | $1.9M | $2.6M | $8.4M |
| Short-term investments | $0.00 | $0.00 | $2.9M | $0.00 |
| Total debt | $0.00 | $670.2K | $841.5K | $0.00 |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975.7K |
| Shareholders' equity | $2.3M | $709.2K | $4.1M | $7.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology